257 related articles for article (PubMed ID: 26909248)
1. Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.
Heymann D
J Bone Oncol; 2012 Jun; 1(1):2-11. PubMed ID: 26909248
[TBL] [Abstract][Full Text] [Related]
2. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
3. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
4. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
5. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
6. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
[TBL] [Abstract][Full Text] [Related]
7. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts.
O' Gradaigh D; Ireland D; Bord S; Compston JE
Ann Rheum Dis; 2004 Apr; 63(4):354-9. PubMed ID: 15020327
[TBL] [Abstract][Full Text] [Related]
8. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
9. From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights.
Anesi A; Generali L; Sandoni L; Pozzi S; Grande A
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590328
[TBL] [Abstract][Full Text] [Related]
10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
11. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
12. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
13. Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion.
Kitazawa R; Haraguchi R; Fukushima M; Kitazawa S
Histochem Cell Biol; 2018 Apr; 149(4):405-415. PubMed ID: 29356963
[TBL] [Abstract][Full Text] [Related]
14. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
15. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Romas E; Gillespie MT; Martin TJ
Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
[TBL] [Abstract][Full Text] [Related]
16. Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.
Sabokbar A; Mahoney DJ; Hemingway F; Athanasou NA
Clin Rev Allergy Immunol; 2016 Aug; 51(1):16-26. PubMed ID: 26578261
[TBL] [Abstract][Full Text] [Related]
17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
18. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
19. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts.
Wright LM; Maloney W; Yu X; Kindle L; Collin-Osdoby P; Osdoby P
Bone; 2005 May; 36(5):840-53. PubMed ID: 15794931
[TBL] [Abstract][Full Text] [Related]
20.
Chakraborty S; Kloos B; Harre U; Schett G; Kubatzky KF
Front Immunol; 2017; 8():185. PubMed ID: 28289415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
